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Abstract We investigated the mechanisms that regulate the 
efficacy of agonists in the arginine-vasopressin (AVP)/oxytocin 
(OT) receptor system. In this paper, we present evidence that 
AVP, a full agonist of the vasopressin receptors, acts as a partial 
agonist on the oxytocin receptor. We also found that AVP 
becomes a full agonist when two aromatic residues of the 
oxytocin receptor are replaced by the residues present at 
equivalent positions in the vasopressin receptor subtypes. Our 
results indicate that these two residues modulate the response of 
the oxytocin receptor to the partial agonist AVP. 
Key words: Oxytocin receptor; Vasopressin; G protein 
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1. Introduction 
Evolutionarily related peptides of the oxytocin (OT)/vaso- 
pressin (AVP) family are found throughout the animal king- 
dom [l]. These hormones bind to and activate a number of 
receptor subtypes: in mammals, one oxytocin receptor (OTR) 
[2,3] and three vasopressin receptors (Vla, Vlb and V2) [4-91 
have been recently cloned; closely related receptors have also 
been identified in bony fish and invertebrates [lO-121. All of 
the OT and AVP receptors cloned so far belong to the 7 
transmembrane spanning domain receptor family and are 
characterised by a high degree of sequence homology. The 
neurohypophyseal peptides are also structurally linked : they 
are all characterised by the presence of a cyclic backbone 
formed by six amino acids and a short C-terminus tripeptide. 
In a previous study, we showed that the high affinity bind- 
ing of AVP and related peptides is mainly determined by 
interactions of the hormones with the residues located in the 
transmembrane part of the Vla receptor [13]. These residues 
are conserved in all of the OT/AVP receptors cloned so far, 
suggesting that a common binding pocket is shared by all of 
these receptor subtypes. On the other hand, it is very likely 
that the selective actions of the different peptides on the dif- 
ferent receptor subtypes are due to interactions involving non- 
conserved peptide and/or receptor residues. OT and AVP, the 
two nonapeptides present in humans, differ in terms of two 
residues: one is located at position 3 in the cyclic part of the 
peptide, the other at position 8 in the linear part (Table 1). 
We have previously shown that part of the binding selectivity 
in neurohypophyseal receptors is due to the interaction be- 
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tween the lateral chain of peptide residue 8 and a receptor 
residue located in the first extracellular loop [14] (see also 
[15]). In the present study, we investigated in detail the bind- 
ing and coupling properties of the cloned human OTR and 
the role played by the interactions of peptide position 3 in 
determining the pharmacological properties of the agonist re- 
sponse. 
2. Materials and methods 
2.1. Drugs 
A$-vasopressin (AVP), arginines-vasotocin (AVT), PhezOm8-va- 
sotocin (Phe20rna-VT) and oxytocin (OT) came from Bachem, 
France. Thr4Gly7-oxytocin (Thr4Gly70T), Phe3-oxytocin (Phe30T) 
and the OT receptor antagonist d(CHs)s[Tyr(Me)2,Thr‘i,Tyrg- 
NHs]OVT (OTA) were synthesised in the laboratory of Dr. M. Man- 
ning; the OTA was iodinated as previously described [16]. [3H]Args- 
vasopressin ([3H]AVP) and [3H]oxytocin (rH]OT) (6tk-80 Ci/mmol) 
came from DuPont-NEN. 
2.2. Mutagenesis and transfection 
The human OT cDNA [2] receptor was a generous gift from Dr. T. 
Kimura. The mutants were constructed by means of oligonucleotide- 
directed mutagenesis (Sculptor Kit, Amersham). COS7 cells, mouse L 
fibroblasts (LTK- cells) and CHO cells were from the American Type 
Culture Collection. For transfection, the wild type and mutant OTR 
cDNAs were inserted in an expression vector under the control of the 
CMV promoter. Transient transfections in COS7 cells were performed 
by means of electroporation as described [14]. The CHO and LTK- 
cells were transfected with DOTAP (Boehringer Mannheim) accord- 
ing to the manufacturer’s instructions; stable clones were selected on 
the basis of their resistance to neomycin sulphate (used at a concen- 
tration of 200 kg/ml for LTK- cells and 400 @ml for CHO cells). 
2.3. Binding assays and inositol phosphates measurements 
[iz51]OTA, [3H]AVP and [3H]OT were used for Scatchard analysis 
and competition experiments on cell homogenates [13,14]. The bind- 
ing data were analysed by means of Ligand [17]. Inositol phosphates 
(InsPs) accumulation was determined as described [14,18]. The data 
were analysed by means of non-linear regression using a sigmoidal 
dose-response equation (Graph Pad Prism). 
2.4. Computer modelling 
The modelling of the oxytocin receptor was based on the same 
procedures already used for modelling the rat Vla receptor, and ex- 
tensively described in a previous paper [13]. 
3. Results and discussion 
3.1. Agonist selectivity of the human OTR 
In order to better characterize the agonist selectivity of the 
cloned human OTR, we studied the binding properties of this 
receptor and its activation by OT and AVP in transiently 
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Table 1 
Inhibition constants (Ki in nM) for the wild-type and mutant receptors 
Analogue OTR OTR OTR 
o-r 
AVP 
Fi&T 
AVT 
I?GOldVT 
ThfQY7m 
PIPTA 
wikiqpe Y5CBF F609Y 
~yel-1Lr2_Ile3-Gln4_Asn5-~ys6-pro7-Leu8-Gl~9-~~ 0.79 + 0.22 0.31* 0.07 ox%* 0.12 
~sl-ILr2_phe3_Gln4_Asn5_~a6-Pro7-prg8-Gly9-NHZ 1.65 f 0.49 1.41 k 0.160 3.6 * 0.7 
I 
dysl_lL12-Phd_Gln4-Asn5-Cya6-pro7-Leu8-Gly9-NH2 1.54 + 0.53 0.53 f 0.03 11.3 + 3.4 
~ysl_lL12_Ile3_Gln4-Asn5-~ye6-pro7-Arg8-GLy9-NH;! 0.36 f 0.10 0.25 f 0.11 1.86 f 0.9 
~ye1_P~~-Ile3_G~n4_Asn5-~ys6-~ro7~m8-~~9-~2 21.9 + 3.30 7.23 k 0.50 92.00 It 17.4 
~ys1_1L,2_Ile3_?hr4_Asn5-~ye6-Gly7-Leu8-Gly9-Mi2 6.6 f 1.22 0.99 + 0.35 17.65 + 4.2 
0.09 + 0.03’ 3.62 + 1.27’ 0.19 + 0.02O 
For the wild-type OTR and the OTR mutant F609Y, the K, values were obtained by means of the displacement of [iz51]OTA, after determina- 
tion of the antagonist Kd values (indicated by 0) using Scatchard analysis. The Ki values for the OTR mutant F509Y were obtained by means 
of displacement of [3H]AVP (Kc1 value indicated by O); l indicates the Ki value obtained for the unlabelled iodinated I-OTA. In competition 
experiments, the labelled ligands were used at a concentration which approximately equals the Kd determined in the saturation experiments 
(100-200 pM for [iz51]OTA; 24 nM for [“HIAVP). All of the values are the means+S.E.M. of at least three different experiments each per- 
formed in triplicate. The amino acid sequence of the peptide analogues is reported in the three-letter code. 
transfected COS7 cells and in stably transfected CHO and 
LTK- cells. 
As shown in Table 1, the cloned human OTR expressed in 
COS7 cells binds OT, AVP, AVT, Phe3-OT and the selective 
OTR agonist Thr4Gly7-OT [19] with similar affinity; it also 
binds the selective Vla agonist Phe20rns-VT [20], although 
with a lower affinity. In LTK- and CHO cells expressing the 
OTR at similar levels (&a values reported in Table 2) no 
significant differences in the binding affinities of [‘251]OTA, 
OT and AVP were observed (data not shown). These binding 
properties indicate that the cloned human OTR may corre- 
spond to one of the high affinity binding sites for OT char- 
acterised in the human myometrium, in particular to the site 
which has been shown to bind OT, AVP and AVT with com- 
parable affinity [21]. 
The cloned human OTR therefore appears to be an unse- 
lective receptor for OT and AVP when only the binding af- 
finities of these two peptides are considered. However, it is 
known that OT and AVP induce very different responses on 
uterine contractility and PLC activation [21-241. Differences 
in the capability of OT and AVP to activate the human OTR 
may contribute to determining OT versus AVP selectivity, a 
Table 2 
Coupling properties of the wild-type and mutant OTRs 
possibility that has never been investigated in details. To elu- 
cidate this point, we determined the efficacies of OT and AVP 
on the human OTR by performing dose-response curves of 
InsPs accumulation in LTK-, CHO and COS7 cells (Fig. lA- 
C). No difference in maximal OT stimulation was observed in 
the three cell types used. Under our experimental conditions, 
OT induced a maximal 3%5-fold increase in total InsPs pro- 
duction when applied at a concentration of 10 ,uM. AVP 
maximal response at the same concentration (10 PM) was 
always less than 60% that of maximal OT stimulation in 
both the transiently and stably transfected cells (Table 2), 
suggesting that AVP can be considered a partial agonist on 
the cloned human OTR. Our data indicate that neither the 
type of transfection nor the cell line used affect the intrinsic 
activity of AVP on the human OTR. However, it has been 
recently shown that the efficacy of agonists in transfected cells 
may be greatly influenced by the level of receptor expression 
[25-271. A low level of receptor expression might lead to a 
molecule being considered a partial agonist, whereas the 
greater number of receptors expressed in vivo might lead it 
to behave as a full agonist. To avoid this problem, we selected 
cells that express a large number of receptors (0.5-2 pmol/mg 
Human OT receptor 
WT in CHO 
GT EC50 (nW 
12.9f4.2 (n=5) 
AVP ECsa (nM) 
316f95 (n=5) 
AVP intrinsic activity 
49 f 3.4% (n = 5) 
Receptor density (pmol/mg) 
0.99 f 0.03 (n = 2) 
WT in LTK- 6.3f0.S (n=7) 75f34 (n=2) 58 f 0.5% (n = 2) 0.53f0.14 &=4j 
WT in COS7 4.8 + 0.8 (n = 7) 81f19 (n=4) 59 f 2.0% (n = 7) 1.73f0.30 (n=6) 
Y509F in COS7 0.45kO.2 (n=4) 47 + 5.4 (n = 3) 87 f 4.9% (n = 7) 0.85 t 0.39 (n = 3) 
F609Y in COS7 2.9 + 0.69 (n = 4) 115f65 (n=4) 88 f 4.3% (n = 7) 1.47 f 0.35 (n = 5) 
The EC’,0 values of OT and AVP were obtained by analysing the dose-response curves of InsP production (shown in Fig. 1) with a non-linear 
regression equation (GraphPad Prism). To evaluate the intrinsic activity of the peptides, the levels of total InsP accumulation induced by OT and 
AVP, at the concentration of 1O-5 M, were determined in parallel in several independent experiments. For each determination, AVP intrinsic 
activity was calculated as the % of the maximal OT stimulation obtained. Receptor density was determined in saturation experiments using the 
specific antagonist [iz51]OTA for the wild-type OTR and the F609Y mutant and with [“H]AVP for the Y509F mutant; the values are expressed as 
pmoNmg of membrane proteins. All of the values are expressed as means +_ S.E.M. 
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A) OTRWT B) OTRWI- 
CHO cells LTK- cells 
log [peptide] 
D) OTRY509F 
COS7 cells 
as3 -,1-,0-s -8 -7 -6.5.4 
log [peptide] 
E) OTRF609Y 
COS7 cells 
Fig. 1. Analysis of second messenger responses of wild-type and mutant OTRs. For the wild type OTR, the accumulation of inositol phos- 
phates induced by increasing doses of OT and AVP was measured in stably transfected CHO cells (A), stably transfected LTK- cells (B) and 
transiently transfected COS7 cells (C). The coupling efficiency of OTR mutants Y509F and F609Y to PLC was assayed in transiently trans- 
fected COS7 cells (D, E). The curves are representative of at least three independent assays performed in triplicate. Each point represents the 
total amount of inositol phosphates (total InsP) and is expressed as DPMlwell. Fitting was obtained by means of non-linear regression (Graph- 
Pad Prism Software). To evaluate the intrinsic activity of the peptides, the levels of total InsPs accumulation induced by OT and AVP at a 
concentration of IO-’ M were determined in parallel in several independent experiments. For each determination, AVP intrinsic activity was 
calculated as the % of the maximal OT stimulation obtained. The mean values f S.E.M. of the intrinsic activity obtained for AVP on the wild- 
type and mutant OTRs are shown in Table 2. 
of proteins), which is approximately equal to the number of 
OTR present in the human uterus at term parturition (0.6 
pmollmg of proteins) [21]. 
The OT ECse values in COS7 and LTK- cells (Table 2) 
were comparable with those obtained in human cells expres- 
sing endogenous OTRs [23,28]. However, slightly higher EC& 
values were observed in CHO cells, probably because of dif- 
ferences in the transduction components present in this cell 
type, as has already been observed for the human Vla recep- 
tor [5]. Our data indicate that AVP is less potent than OT in 
all of the three cell lines considered; we found that a 100 times 
higher concentration of AVP was necessary to elicit the same 
response as that induced by OT, a result also obtained on the 
cloned human OTR expressed in Xenopus oocytes [29]. Thus, 
although OT and AVP have a very similar binding affinity, 
their EC& differ by a factor of at least 10: a lower ECsO for 
AVP is to be expected if this analogue is only a partial agonist 
of the human OTR [30]. 
In conclusion, these data indicate that AVP is a partial 
agonist of the human OTR, a pharmacological property 
that may contribute to its selective physiological action in 
vivo. 
3.2. Molecular modelling of the human OTR 
In order to identify the interactions that may contribute to 
determine the agonist selectivity of the human OTR, we con- 
structed a three-dimensional model of the receptor and 
docked the two ligands OT and AVP. The OTR model was 
based on our previous work on the Vla vasopressin receptor 
in which we analysed the hydrogen bonding and ionic inter- 
actions between the peptide agonists and several transmem- 
brane receptor residues. Our results strongly supported the 
binding of OT and AVP to a pocket located in the upper 
part of the receptor transmembrane domains [13]. 
Since it is known that substitutions in peptide positions 2 
and 3 greatly affect the efficacy of the neurohypophyseal pep- 
tides, we made a molecular analysis of the interactions of 
these residues within the binding pocket of the human 
OTR. In our model, a network of aromatic-aromatic and 
hydrophobic-aromatic interactions can be observed between 
Tyr’ and Ile” of OT and TyrSog, PheGog, Phe”16, Trp613, 
PheG1” and Phe617 of the OTR (Fig. 2). (To facilitate the 
comparison, the residues have been numbered as previously 
defined [31]: the left digit indicates the transmembrane do- 
main number, and the following two digits indicate the rank 
of the residue in this domain.) Interestingly, most of these 
aromatic receptor residues, located at the bottom of the ago- 
nist binding pocket, are conserved in a large number of opsin- 
like G protein coupled receptors (GPCRs), suggesting that the 
3 
Fig. 2. Schematic presentation of oxytocin docked in the human 
OTR. The extracellular regions and the two thirds of the transmem- 
brane domains of the receptor are shown from a direction parallel 
to the cell membrane; the arrows indicate the limit of the lipid bi- 
layer. Transmembrane domains (numbered I-VII) are arranged an- 
ticlockwise; only the Ca-carbon backbone of the receptor is shown, 
with the exception of the side chains of residues 509, 609, 613, 616 
and 617. Receptor residues are labelled according to the following 
rule: the left digit indicates the number of the transmembrane a-he- 
lix, the next two digits indicate the rank of the residue in this trans- 
membrane region (e.g. Phesos IS the 9th residue of helix 5). Oxytocin 
is positioned inside the putative agonist binding pocket; all the side 
chain residues of the peptide (numbered l-9) are shown. 
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TMR5 509 
humanOTR ITWITLAV$&$IVPVIVLATCYGL 
rat OTR 
..i .. .._. . . . .
human Vla 
VTWITLAV@!IVPVIVLAACYGL 
VTWNTGGI$@$VAPVVILGTCYGF 
rat Vla 
:.:+.:.:.:.: 
VTWNTSGV$$@VAPVVVLGTCYGF ..i .i....... 
human Vlb 
. i........... 
VTWTTLGI$#$VLPVTMLTACYSL . . ..i.... 
rat Vlb 
ii.%........ 
human V2 
ITWTTMAI$$@$VLPVAVLTACYGL 
VTWIALMVj$#$VAPTLGIAACQVL 
rat V2 
ii.>..../.. ..i .I.... I 
VTWIALMV$#$VAPALGIAACQVL 
fish AVT ITWITVGIS~~LIPVVILMISYGL 
fish IST ITWISLTI~~IIpVAILGGCyGL 
LSCPRl 
$$::::;::: 
ITWVFVAN$$iVIPFLLLAFCYGR . . . 
TMR6 609 
human0”l-R MTFIIVLAI~~IVCWTPFFFVQMW _.... .A../.. 
rat OTR 
i....  . . . . . . 
human Vla 
MTFIIVLA##$IVCWTPFFFVQMW :...... 
MTFVIVTA$@IVCWAPFFIIQMW 
rat Vla 
../........... 
MTFVIVSA$:@;ILCWAPFFIVQMW . i........... 
human Vlb 
.,.::,.::, 
MTFVIVLA$$g;IACWAPFFSVQMW 
rat Vlb MTFVIVLAjii~IACWAPFFSVQMW 
human V2 
: :.>::.>:. 
MTLVIVIV;iiii:#jVLCWAPFFLVQLW 
rat V2 
. . . . . . . . . . . . . . . . .I. 
MTLVIVVViiiij!VLCWAPFFLVQLW 
fish AVT MTLVIVLA~~~IVCWAPFFIVQMW . . . . . . . . .../.. 
fish IST 
.\.......... 
MTFVIVLA$@IVCWTPFFFVQMW 
LSCPRl 
::::::::‘:::::: 
LTLTVVLC$@LFCWAPFFVVQMW 
Fig. 3. Comparison of the amino acid sequences of transmembrane regions 5 and 6 of the human and rat oxytocin receptors (OTR) [2,3], Via 
vasopressin receptors [4,5], Vlb vasopressin receptors [6,7] and V2 vasopressin receptors [8,9]; as well as those of the teleost fish Catostomus 
commersoni receptors for Arg-vasotocin (AVT) and Isotocin (IST) [lO,ll], and the mollusc Lymnaea stagnalis receptor for Lys-conopressin 
(LSCPRl) [12]. Residues at position 509 and 609 in the OT/AVP receptor subtypes are printed in bold and shadowed. 
aromatic cluster may play a key role in regulating the agonist- 
receptor interactions, as has previously been proposed [31]. 
Since residues 509 and 609 are not conserved between OT 
and AVP receptors (Fig. 3), similar, but not identical interac- 
tions can be predicted between residues 2 and 3 of the peptide 
agonists and the aromatic cluster present in the different re- 
ceptor subtypes. We proposed that residues 509 and 609 may 
thus play a pivotal role in regulating agonist efficacy in the 
human OTR and this hypothesis was experimentally investi- 
gated. 
3.3. Mutations Y5’09F and F609 Y convert A VP from a partial 
to a fill agonist of human OTR 
Residues 509 and 609 were subjected to site-directed muta- 
genesis in the human OTR, and the pharmacological proper- 
ties of the mutant receptors were assayed in transiently trans- 
fected COS7 cells. 
Two preliminary mutations, in which the two residues were 
substituted by alanine residues, led to receptors with no meas- 
urable binding affinity for either agonists or antagonists; 
furthermore, no agonist-stimulated production of InsPs was 
observed (data not shown). These findings indicate that these 
two residues are critical in determining the folding and/or 
functional properties of the receptor. Their important func- 
tional role is further supported by the finding that natural 
point mutations at these two positions have been identified 
in the vasopressin V2 receptors of two families of patients 
with X-linked nephrogenic diabetes insipidus [32,33]. A num- 
ber of mutations have recently been described in patients suf- 
fering from this pathological condition, including some which 
have already been proved to cause a loss of V2 receptor func- 
tion (see [34] for review); the two natural mutations involving 
residues 509 and 609 also certainly deserve careful functional 
investigation. 
We then produced two receptor mutants in which residues 
509 and 609 were replaced by the amino acids present in the 
vasopressin receptor subtypes: TyrSog was converted into a 
Phe (Y509F mutant) and Phe60g into a Tyr (F609Y mutant). 
Substitutions with aromatic residues are less likely to perturb 
the folding or overall structure of the receptor dramatically 
and, in fact, the expression of the receptor mutants was com- 
parable with that observed for the wild-type OTR, as deduced 
from the B,,, values determined in saturation experiments 
(Table 2). 
As shown in Table 1, both of the receptor mutants main- 
tained their ability to bind all of the tested agonists and an- 
tagonists: in the case of mutant Y509F, there was a slight 
increase in the affinity for some agonists (OT, Phe3-OT, 
Phe’Orn’-VT, Thr4Gly7-OT), whereas the affinity of the spe- 
cific OTR antagonist OTA was decreased by a factor of 38. In 
the case of the F609Y mutant, there was no change (OT) or a 
slight reduction in the binding affinities for some agonists 
(AVP, Phe3-OT, AVT, Phe20rns-VT, Thr4Gly7-OT), whereas 
the OTA affinity remained unchanged. These data indicate 
that residues 509 and 609 do not contribute to the high affin- 
ity binding of these analogues to the human OTR. 
Since our data indicate that AVP is a partial agonist of the 
human OTR, and that this property does not depend on the 
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cell line expressing the receptor, we performed dose-response 
curves of total InsPs accumulation only in the transiently 
transfected COS7 expressing the mutant Y509F and F609Y 
receptors (Fig. lD,E). With both mutants, the intrinsic activ- 
ity of OT itself was not significantly affected: it produced a 
maximal 3-5-fold increase in total InsPs over baseline, the 
same degree of stimulation as that observed with the wild- 
type receptor. In addition, the dose-response curve extended 
over an agonist concentration range of two orders of magni- 
tude, suggesting that the reaction obeys the classical mass law 
action and that the system is not saturated. However, the 
intrinsic activity of AVP increased dramatically, becoming 
respectively 87% (n = 7; P < 0.001) and 88% (n = 7; P < 0.001) 
of the maximal OT stimulation in the Y509F and F609Y 
OTR mutants (Table 2). Our data indicate that the intrinsic 
activity of AVP is greatly modified in the two mutated recep- 
tors. 
It is now generally accepted that GPCRs exist as a popula- 
tion of metastable conformers whose intrinsic dynamics and 
distribution are modulated by various factors : the presence of 
proline residues in the a-helical transmembrane domains; the 
length of the connecting loops, which may possibly even allow 
the sub-domains a certain relative motion; and finally the 
network of side chain-side chain interactions between adja- 
cent transmembrane domains (see [35-381 and references 
therein). The ligands may have a preferential affinity for a 
given pre-existing side-chain network (conformational selec- 
tion theory), or they may be regarded as agents capable of 
perturbing the system by triggering a reorganisation of the 
network of interactions (conformational induction theory) 
([39] and references therein); it is most probable that the 
two phenomena coexist. 
Our mutagenesis data do not make it possible to distinguish 
between the two theories, although we can suggest that muta- 
tion Y509F is more likely to affect the spontaneous equili- 
brium between the inactive (R) and active receptor (R’) states. 
In this mutation, we observed a generalised increase in affinity 
for almost all of the agonists tested, with a parallel decrease in 
the affinity for the specific OTR antagonist OTA; we also 
observed lo-fold lower ECso values for OT which probably 
reflect the 3-fold increase in the affinity of this analogue. Sim- 
ilarly, a slight decrease in the ECso of AVP was observed, 
even if in this case no significant change in AVP affinity 
was measured. Unfortunately, we were not able to detect 
any significant and reproducible increase in its basal activity, 
a finding that would have strongly supported this hypothesis. 
In the case of mutation Y609F, a decrease in the affinity for 
some agonists was observed, with no change in either the 
potency or intrinsic activity of OT itself. Similarly, the affinity 
of the specific antagonist [‘251]OTA remained unchanged. In 
this case, a direct interactions between residue 609 and the 
aromatic residues 2 and/or 3 of the peptides may contribute 
towards the intrinsic efficacy of the ligand-receptor complex, 
an hypothesis that will need further studies to be experimen- 
tally validated. 
A limited number of direct ligand-receptor contacts have 
been shown to modulate the coupling efficacy of GPCRs: 
these include hydrogen bonding interactions, as in muscarinic 
receptors [40]; ionic interactions, as in P-adrenergic and an- 
giotensin II receptors [41,42]; and now the aromatic-hydro- 
phobic interactions described here for the OT/AVP receptors. 
It can be presumed that a few residues will be found to play a 
205 
general role in stabilising active conformations in different 
receptor subtypes, whereas specific peptide-receptor interac- 
tions regulating agonist efficacy will be found in each receptor 
family. It is worth mentioning that aromatic residues are pres- 
ent at positions 509 and 609 in most rhodopsin-like GPCRs; 
we therefore think that these residues may modulate the proc- 
ess of receptor activation in various members of the GPCR 
family. 
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